Subtyping Diffuse Large B-Cell Lymphoma with Cell-of-Origin Using 32-Gene Expression Assay in Formalin-Fixed Paraffin-Embedded Tissue

Introduction Diffuse large B-cell lymphoma (DLBCL) is a group of heterogeneous disease with distinct molecular subtypes. The most established subtyping algorithm, the Cell-of-Origin (COO) model, categorizes DLBCL into activated B-cell (ABC) and germinal center B-cell (GCB)-like subgroups through gen...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2019-11, Vol.134 (Supplement_1), p.5337-5337
Main Authors: Jiang, Xiangnan, Yan, Wanhui, Sun, Yifeng, Xu, Qinghua, Zhou, Xiaoyan, Cao, Junning, Hong, Xiaonan, Li, Xiaoqiu
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Diffuse large B-cell lymphoma (DLBCL) is a group of heterogeneous disease with distinct molecular subtypes. The most established subtyping algorithm, the Cell-of-Origin (COO) model, categorizes DLBCL into activated B-cell (ABC) and germinal center B-cell (GCB)-like subgroups through gene expression profiling. COO subtyping is mandatory for every newly diagnosed DLBCL patients, as it is critical for determining the therapeutic and surveillance strategies. We evaluated a newly developed assay using 32-gene expression profiling to determine the COO of DLBCL with formalin-fixed paraffin-embedded (FFPE) tissue. Methods The DLBCL-COO Test is a qPCR-based 32-gene expression assay for COO determination in FFPE samples. Biopsy of DLBCL patients with paired FFPE and fresh tissue were identified to assign COO, based on the immunohistochemistry (IHC) algorithm (Han's algorithm), DLBCL-COO qPCR assay and global gene expression profiling with RNA-seq, respectively. The global gene expression profiling with RNA-seq was taken as the “gold standard” for reference. Clinical information including the survival data were collected. Results 160 cases of DLBCL with evaluable COO assignments with IHC, DLBCL-COO 32-gene assay and global gene expression profiling with RNA-seq were identified. Comparing with the 77.5% concordance between IHC algorithm and gold standard, there is 91.9% concordance between DLBCL-COO 32-gene assay and gold standard (P = 0.005). 72 patients assigned as ABC subtype and 14 patients assigned as Type-3 subtype demonstrated a significantly inferior overall survival than 42 patients assigned as GCB subtype using DLBCL-COO assay (P = 0.023). However, COO based the IHC algorithm failed to provide the predictive value regarding overall survival (P = 0.09). Conclusions DLBCL-COO assay provides flexibility and accuracy in DLBCL subtype characterization. These subtype distinctions should help guide disease prognosis and treatment options within DLBCL clinical practice. Sun:Canhelp Genomics: Employment. Xu:Canhelp Genomics: Employment.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2019-126629